Abstract
Background: There exists a need for more sensitive measures capable of detecting subtle cognitive decline due to Alzheimer's disease.
Objective: To advance the literature in Alzheimer’s disease by demonstrating that performance on a cued-Stroop task is impacted by preclinical Alzheimer's disease neuropathology.
Method: Twenty-nine cognitively asymptomatic older adults completed a computerized, cued-Stroop task in which accuracy rates and intraindividual variability in reaction times were the outcomes of interest. Cerebrospinal fluid biomarkers of Aβ42 and tau were measured and participants were then grouped according to a published p-tau/Aβ42 cutoff reflecting risk for Alzheimer’s disease (preclinical Alzheimer's disease = 14; control = 15).
Results: ANOVAs indicated that accuracy rates did not differ between the groups but 4-second delay incongruent color-naming Stroop coefficient of variation reaction times were higher in the preclinical Alzheimer’s disease group compared to the control group, reflecting increased within-person variability. Moreover, partial correlations showed no relationships between cerebrospinal fluid biomarkers and accuracy rates. However, increases in coefficient of variation reaction times correlated with decreased Aβ42 and increases in p-tau and the p-tau/Aβ42 ratio.
Conclusion: Results supported the ability of the computerized, cued-Stroop task to detect subtle Alzheimer’s disease neuropathology using a small cohort of cognitively asymptomatic older adults. The ongoing measurement of cued-Stroop coefficient of variation reaction times has both scientific and clinical utility in preclinical Alzheimer’s disease.
Keywords: Alzheimer's disease, neuropsychology, cognitive neuroscience, Stroop test, biomarkers, intraindividual variability, aging, cognitive decline.
Current Alzheimer Research
Title:Differential Cued-Stroop Performance in Cognitively Asymptomatic Older Adults with Biomarker-Identified Risk for Alzheimer’s Disease: A Pilot Study
Volume: 15 Issue: 9
Author(s): Ryan Van Patten*, Anne M. Fagan and David A.S. Kaufman
Affiliation:
- Department of Psychology, Saint Louis University, St. Louis, MO,United States
Keywords: Alzheimer's disease, neuropsychology, cognitive neuroscience, Stroop test, biomarkers, intraindividual variability, aging, cognitive decline.
Abstract: Background: There exists a need for more sensitive measures capable of detecting subtle cognitive decline due to Alzheimer's disease.
Objective: To advance the literature in Alzheimer’s disease by demonstrating that performance on a cued-Stroop task is impacted by preclinical Alzheimer's disease neuropathology.
Method: Twenty-nine cognitively asymptomatic older adults completed a computerized, cued-Stroop task in which accuracy rates and intraindividual variability in reaction times were the outcomes of interest. Cerebrospinal fluid biomarkers of Aβ42 and tau were measured and participants were then grouped according to a published p-tau/Aβ42 cutoff reflecting risk for Alzheimer’s disease (preclinical Alzheimer's disease = 14; control = 15).
Results: ANOVAs indicated that accuracy rates did not differ between the groups but 4-second delay incongruent color-naming Stroop coefficient of variation reaction times were higher in the preclinical Alzheimer’s disease group compared to the control group, reflecting increased within-person variability. Moreover, partial correlations showed no relationships between cerebrospinal fluid biomarkers and accuracy rates. However, increases in coefficient of variation reaction times correlated with decreased Aβ42 and increases in p-tau and the p-tau/Aβ42 ratio.
Conclusion: Results supported the ability of the computerized, cued-Stroop task to detect subtle Alzheimer’s disease neuropathology using a small cohort of cognitively asymptomatic older adults. The ongoing measurement of cued-Stroop coefficient of variation reaction times has both scientific and clinical utility in preclinical Alzheimer’s disease.
Export Options
About this article
Cite this article as:
Patten Van Ryan *, Fagan M. Anne and Kaufman A.S. David , Differential Cued-Stroop Performance in Cognitively Asymptomatic Older Adults with Biomarker-Identified Risk for Alzheimer’s Disease: A Pilot Study, Current Alzheimer Research 2018; 15 (9) . https://dx.doi.org/10.2174/1567205015666180404170359
DOI https://dx.doi.org/10.2174/1567205015666180404170359 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Thromboembolic Complications in Malignant Haematological Disorders
Current Vascular Pharmacology Impaired Cognitive Function is Associated with Motor Function and Activities of Daily Living in Mild to Moderate Alzheimer's Dementia
Current Alzheimer Research Role of Perindopril in the Prevention of Stroke
Recent Patents on Cardiovascular Drug Discovery The Endocannabinoid System: A Promising Target for the Management of Type 2 Diabetes
Current Protein & Peptide Science Elevated Aβ42 in Aged, Non-demented Individuals with Cerebral Atherosclerosis
Current Alzheimer Research Sleep and Antidepressant Treatment
Current Pharmaceutical Design Antidepressants: Update on Benefits and Risks
Current Psychopharmacology Alzheimer’s Disease: Physical Activities as an Effective Intervention Tool - A Mini-Review
Current Alzheimer Research Parkinsons Disease: Genetics and Beyond
Current Neuropharmacology Changing the Course of Alzheimers Disease: Emerging Disease Modifying Therapies
Current Psychiatry Reviews Inflammation in Ischemic Stroke Subtypes
Current Pharmaceutical Design Aspirin Resistance in Cardiovascular Disease: Pathogenesis, Diagnosis and Clinical Impact
Current Pharmaceutical Design Metal Ions and Metal Complexes in Alzheimer’s Disease
Current Pharmaceutical Design Amyloid Beta-Weighted Cortical Thickness: A New Imaging Biomarker in Alzheimer's Disease
Current Alzheimer Research Scientific and Clinical Challenges in Sepsis
Current Pharmaceutical Design Age-Related Neurodegeneration Prevention Through mTOR Inhibition: Potential Mechanisms and Remaining Questions
Current Topics in Medicinal Chemistry Recent Advances in the Development of Hybrid Molecules/Designed Multiple Compounds with Antiamnesic Properties
Mini-Reviews in Medicinal Chemistry Mechanistic Modeling of Soluble Aβ Dynamics and Target Engagement in the Brain by Anti-Aβ mAbs in Alzheimer’s Disease
Current Alzheimer Research Mitochondrial Pharmaceutics: A New Therapeutic Strategy to Ameliorate Oxidative Stress in Alzheimer’s Disease
Current Aging Science Silymarin Extends Lifespan and Reduces Proteotoxicity in C. elegans Alzheimer’s Model
CNS & Neurological Disorders - Drug Targets